Sequence: CGRRMKWKK
| Experiment Id | EXP000786 |
|---|---|
| Paper | Polymer nanoparticles modified with photo- and pH-dual-responsive polypeptides for enhanced and targ |
| Peptide | CPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 20 µg/kg (siRNA); 1.2 mg/kg NPs |
| Mixing Ratio | |
| Formulation Format | PLGA nanoparticles (w/o/w double emulsion) PEGylated with DSPE-PEG2000; surface ligand DSPE-PEG2000-peptide; siRNA encapsulated as siRNA–spermidine complex |
| Formulation Components | PLGA (50/50); DSPE-PEG2000; PVA; siRNA–spermidine complex |
| Size Nm | 113.68 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Female BALB/c nude mice with subcutaneous MCF-7 tumor xenografts |
| Administration Route | i.v. tail vein |
| Output Type | tumor growth inhibition (relative tumor volume, day 18) |
| Output Value | RTV 411 ± 40% (EGFR-siRNA CPP-NPs) |
| Output Units | |
| Output Notes | EGFR-siRNA dose 20 µg/kg (NP dose 1.2 mg/kg), injected every other day ×5. Antitumor efficacy weaker than PPP-NPs with NIR (attributed to non-selective penetration), but still lower RTV than glucose control. Encapsulation efficiency ~87%. |
| Toxicity Notes | No remarkable body weight changes among groups during treatment; NIR regimen chosen to avoid burning (tumor temperature increase <1°C). |
| Curation Notes |